source
- Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.onclive · 2mo ago↗ source
- CellCentric raises $220M to get multiple myeloma pill to marketCellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options. The 22-year-old transatlantic biotech has collected a $220 mill…Endpoints · 2mo ago↗ source
- CellCentric raises $220M for a ‘transformative’ multiple myeloma medicineA Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.